Krystal Biotech (KRYS) Total Current Liabilities (2016 - 2026)

Krystal Biotech has disclosed Total Current Liabilities across 11 years of filings, most recently posting $107.8 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $107.8 million, up 35.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $107.8 million (up 35.62% YoY), and the FY2025 annual result was $102.9 million, up 0.93% from the prior year.
• Total Current Liabilities came in at $107.8 million for Q1 2026 at Krystal Biotech, up from $102.9 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $107.8 million in Q1 2026 to a low of $23.9 million in Q2 2023.
• The 5-year median for Total Current Liabilities is $60.4 million (2022), against an average of $61.8 million.
• Across the five-year window, Total Current Liabilities surged 560.95% in 2022 and tumbled 41.96% in 2023, its largest moves.
• Krystal Biotech's Total Current Liabilities stood at $28.8 million in 2022, then advanced by 14.72% to $33.1 million in 2023, then surged by 208.2% to $102.0 million in 2024, then climbed by 0.93% to $102.9 million in 2025, then grew by 4.72% to $107.8 million in 2026.
• The last three Total Current Liabilities figures came in at $107.8 million (Q1 2026), $102.9 million (Q4 2025), and $91.3 million (Q3 2025), per Business Quant data.